Kaia Ordal supports clients with research and analysis that span a variety of healthcare sectors and stakeholders.

She applies her background in health policy and Medicare to a broad range of client projects.

Prior to joining Avalere, Kaia held a variety of internship positions, including an internship with Better Medicare Alliance where she supported the Government Affairs team by tracking state and federal Medicare Advantage policy and attended meetings with member offices on Capitol Hill. Additionally, she supported the Association of American Medical Colleges as the Academic Medicine intern, assisting the journal with administrative and research support. She also has health policy research experience both on Capitol Hill and in a state gubernatorial campaign.

Kaia has a BA in political science and predictive health from Emory University.

Authored Content


In November 2020, the Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to COVID-19 monoclonal antibodies for treatment of mild-to-moderate COVID-19 infection.

Since the beginning of the Public Health Emergency (PHE), manufacturers have been developing monoclonal antibodies (mAbs) and other treatment modalities to prevent and treat COVID-19.

The Centers for Medicare & Medicaid Services (CMS) released coding and payment instructions associated with the first physician-administered outpatient COVID-19 therapeutic. The release specifies that during the public health emergency (PHE), Medicare will cover and pay for these infusions in the same way it does for COVID-19 vaccines.

On February 27, Avalere experts discussed the latest policy, pricing, and reimbursement challenges for prescription drugs in Medicaid in the “What’s Next for Medicaid Drug Pricing?” webinar. They reviewed the ways prescription drugs are managed in Medicaid, what innovative medicines may mean for the program, and potential implications of CMS’ Healthy Adult Opportunity (HAO).